GeoVax Labs, Inc. (NASDAQ:GOVX) Given Consensus Recommendation of “Buy” by Brokerages

GeoVax Labs, Inc. (NASDAQ:GOVX) has earned a consensus rating of “Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $14.20.

Separately, D. Boral Capital reiterated a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research note on Thursday, April 10th.

Hedge Funds Weigh In On GeoVax Labs

Several large investors have recently modified their holdings of GOVX. Virtu Financial LLC acquired a new stake in GeoVax Labs in the third quarter valued at $97,000. Citadel Advisors LLC acquired a new position in GeoVax Labs during the 4th quarter worth about $104,000. Northern Trust Corp bought a new stake in shares of GeoVax Labs in the 4th quarter valued at about $29,000. Finally, Geode Capital Management LLC increased its stake in shares of GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock valued at $223,000 after buying an additional 33,440 shares during the period. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Trading Up 4.9 %

GOVX stock opened at $1.07 on Thursday. The firm has a 50-day moving average price of $1.42 and a 200-day moving average price of $1.98. GeoVax Labs has a 12 month low of $0.88 and a 12 month high of $11.18. The stock has a market capitalization of $14.81 million, a P/E ratio of -0.19 and a beta of 3.70.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.49. The company had revenue of $3.00 million for the quarter, compared to analyst estimates of $2.38 million. As a group, equities analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.